UCB completes the acquisition of Ra Pharmaceuticals - to deliver differentiated ...
(WorldNews Belgium)

· The transaction, which was announced October 10, 2019, will enhance UCB`s potential to be a leader in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab, UCB`s FcRn targeting antibody which is also in phase 3 · Zilucoplan will enhance UCB`s pipeline and Ra Pharma`s ExtremeDiversity[TM ]technology platform will accelerate UCB`s long-term innovation capabilities · The acquisition is expected to enable accelerated top and bottom line company growth from 2024 onwards · Innovative research and development unit in Cambridge, MA adds to UCB`s network and presence in Massachusetts and the...